| Total n = 1833 | High NTS urgency level n = 766 (41.8%) | Low NTS urgency level n = 1067 (58.2%) | p-value |
---|---|---|---|---|
Life-threatening events | ||||
Cardiovascular disorders | ||||
Acute coronary syndrome | 13 (0.7%) | 8 (1.0%) | 5 (0.5%) | 0.166 |
Acute heart failure | 47 (2.6%) | 30 (3.9%) | 17 (1.6%) | 0.002 |
Respiratory tract disorders | ||||
Severe asthma exacerbation | 11 (0.6%) | 6 (0.8%) | 5 (0.5%) | 0.542 |
Severe COPD exacerbation | 38 (2.1%) | 26 (3.4%) | 12 (1.1%) | < 0.001 |
Severe COVID-19 infection | 110 (6.0%) | 56 (7.3%) | 54 (5.1%) | 0.045 |
Severe pneumonia | 34 (1.9%) | 23 (3.0%) | 11 (1.0%) | 0.002 |
Other disorders | ||||
Anaphylaxis | 14 (0.8%) | 1 (0.1%) | 13 (1.2%) | 0.011 |
Pulmonary embolism | 16 (0.9%) | 6 (0.8%) | 10 (0.9%) | 0.804 |
Sepsis | 10 (0.5%) | 7 (0.9%) | 3 (0.3%) | 0.070 |
Other life-threatening events (LTEs)* | 12 (0.7%) | 7 (0.9%) | 5 (0.5%) | 0.256 |
Non-urgent disorders | ||||
Cardiovascular disorders | ||||
Stable heart failure | 39 (2.1%) | 14 (1.8%) | 25 (2.3%) | 0.451 |
Respiratory tract disorders | ||||
Mild or moderate asthma exacerbation | 117 (6.4%) | 39 (5.1%) | 78 (7.3%) | 0.055 |
Mild or moderate COPD exacerbation | 94 (5.1%) | 57 (7.4%) | 37 (3.5%) | < 0.001 |
Mild or moderate COVID-19 infection** | 387 (21.1%) | 141 (18.4%) | 246 (23.1%) | 0.016 |
Mild or moderate pneumonia | 80 (4.4%) | 37 (4.8%) | 43 (4.0%) | 0.408 |
Upper respiratory tract infection | 103 (5.6%) | 26 (3.4%) | 77 (7.2%) | < 0.001 |
Other disorders | ||||
Hyperventilation/anxiety/stress | 136 (7.4%) | 41 (5.4%) | 95 (8.9%) | 0.004 |
Shortness of breath due to (existing) cancer | 34 (1.9%) | 19 (2.5%) | 15 (1.4%) | 0.093 |
Unspecified chest pain*** | 85 (4.6%) | 43 (5.6%) | 42 (3.9%) | 0.092 |
Unspecified shortness of breath*** | 208 (11.3%) | 63 (8.2%) | 145 (13.6%) | < 0.001 |
Other non-urgent disorders**** | 245 (13.4%) | 116 (15.1%) | 129 (12.1%) | 0.058 |